The 2016 revised fourth edition of the World Health Organization (WHO) classification of
central nervous system (CNS) tumors incorporated molecular features with histologic …

Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast
cancer after invasive ductal carcinoma (IDC), accounting for 10–15% of all breast cancer …

The wide variety of clinical manifestations of the genetic syndrome neurofibromatosis type 1
(NF1) are driven by overactivation of the RAS pathway. Mitogen-activated protein kinase …

Son of Sevenless (SOS) is a guanine nucleotide exchange factor that activates the important
cell signaling switch KRAS. SOS acts as a pacemaker for KRAS, the beating heart of cancer …

Abstract On April 10, 2020, the FDA approved selumetinib (KOSELUGO, AstraZeneca) for
the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 …

Simple Summary In the last few years, an increasing number of genotype–phenotype
correlations has been described for neurofibromatosis type 1 (NF1), impacting on the clinical …

Background Pediatric low-grade glioma (pLGG) is essentially a single pathway disease, with
most tumors driven by genomic alterations affecting the mitogen-activated protein …

Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas
(STS) with nerve sheath differentiation and a tendency to metastasize. Although occurring at …

The RASopathies are a group of clinically defined developmental syndromes caused by
germline variants of the RAS/mitogen‐activated protein (MAPK) cascade. The prototypic …

Highlights•PNs are a major cause of morbidity in NF1.•Promising efficacy results with MEK
inhibitors and cabozantinib have been reported.•MEK inhibitors are associated with a …